Loading…
LeMaitre Vascular, Inc. is projected to rise to $108.13 by 2027, a +13% move from its current price of $95.72. LMAT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $93.92 | $95.71 | $97.53 | -0.01% |
| May 30 | $93.17 | $95.69 | $98.28 | -0.03% |
| May 31 | $92.60 | $95.68 | $98.86 | -0.04% |
| Jun 1 | $92.12 | $95.67 | $99.35 | -0.06% |
| Jun 2 | $91.70 | $95.65 | $99.78 | -0.07% |
| Jun 3 | $91.32 | $95.64 | $100.16 | -0.08% |
| Jun 4 | $90.97 | $95.63 | $100.52 | -0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $90.97 | $95.63 | $100.52 | -0.10% |
| Week 2 | $89.02 | $95.53 | $102.52 | -0.20% |
| Week 3 | $87.53 | $95.44 | $104.06 | -0.29% |
| Week 4 | $86.29 | $95.35 | $105.36 | -0.39% |
| Week 5 | $85.19 | $95.25 | $106.50 | -0.49% |
| Week 6 | $84.21 | $95.16 | $107.54 | -0.59% |
| Week 7 | $83.30 | $95.07 | $108.49 | -0.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services.
It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors.
The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
LeMaitre Vascular, Inc. trades at $97.75 per share and has a market capitalization of $2.23B, with a market rank of 1925.
A major floor 13.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 20.1% above — a clean break opens room to run.
A major ceiling 26.9% above — clearing it would confirm fresh momentum.
Key LMAT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LMAT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $98.63 | Sell | $98.07 | Sell |
| MA 10 | $99.03 | Sell | $99.66 | Sell |
| MA 20 | $103.39 | Sell | $102.49 | Sell |
| MA 50 | $108.22 | Sell | $104.50 | Sell |
| MA 100 | $100.25 | Sell | $101.47 | Sell |
| MA 200 | $94.51 | Buy | $96.68 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.65 | Neutral |
| Stoch RSI (14) | 32.94 | Neutral |
| CCI (20) | -99.20 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.57 | Sell |
| ROC (12) | -11.32 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.38 | Sell |
| Awesome (5,34) | -9.06 | Sell |
| Ultimate (7,14,28) | 36.92 | Neutral |
| Momentum (10) | -1.50 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 97.34 | Sell |
| ADX (14) | 22.41 | Sell |
| ATR (14) | 1.88 | Info |
Near-term technical picture shows bullish sentiment with RSI14 at 40. The 50-day simple moving average (SMA50) sits at $108.71, while the 200-day simple moving average (SMA200) is $94.47. Support is noted at $97.22 and resistance at $117.39. The 30-day range spans from $86.34 to $110.66, highlighting a breadth of recent moves. Annualized volatility is 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $80.17 | $95.72 | $129.17 | 0% | Neutral | |
| $88.33 | $108.13 | $138.57 | +13% | Neutral | |
| $91.74 | $114.36 | $150.38 | +19% | Neutral | |
| $103.70 | $131.23 | $176.17 | +37% | Bullish | |
| $116.04 | $148.80 | $203.29 | +55% | Bullish | |
| $137.35 | $178.27 | $247.34 | +86% | Bullish | |
| $148.51 | $194.91 | $274.24 | +104% | Bullish | |
| $152.26 | $201.92 | $287.75 | +111% | Bullish | |
| $164.28 | $220.03 | $317.27 | +130% | Bullish | |
| $168.25 | $227.47 | $331.62 | +138% | Bullish | |
| $247.76 | $349.32 | $533.56 | +265% | Bullish | |
| $448.52 | $678.19 | $1,110.14 | +609% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $80.17 | $95.72 | $112.16 | +0.00% |
| June 2026 | $81.71 | $95.32 | $113.36 | -0.42% |
| July 2026 | $80.55 | $94.51 | $113.45 | -0.85% |
| August 2026 | $82.51 | $97.25 | $117.59 | +2.90% |
| September 2026 | $84.18 | $99.58 | $121.13 | +2.40% |
| October 2026 | $83.75 | $99.41 | $121.58 | -0.17% |
| November 2026 | $84.87 | $101.05 | $124.16 | +1.64% |
| December 2026 | $87.65 | $104.65 | $129.17 | +3.57% |
Click any year to see its month-by-month LMAT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, LMAT is projected to trade between $80.17 and $129.17, averaging $95.72 — a potential gain of 0% from today's $95.72. A consolidation phase looks the most probable path here.
LeMaitre Vascular, Inc.'s 2027 outlook centres on $108.13, within a $88.33 to $138.57 range. That is up +13% on the projected 2026 average. That marks a +13% change versus current levels. Price action looks broadly range-bound.
By 2028, LMAT could reach as high as $150.38, with a base case around $114.36 and support toward $91.74 — roughly +19% from $95.72. A consolidation phase looks the most probable path here.
Expect LMAT to range from $103.70 to $176.17 through 2029. The $131.23 average target implies a +37% move from current prices. That is up +15% on the projected 2028 average. Momentum favours further upside here.
The LMAT price prediction for 2030 points to an average of $148.80 (low $116.04, high $203.29) — a potential gain of +55% on today's $95.72. Buyers look set to stay in control over this stretch.
In 2031, LMAT is projected to trade between $137.35 and $247.34, averaging $178.27 — a potential gain of +86% from today's $95.72. That is up +20% on the projected 2030 average. Momentum favours further upside here.
LeMaitre Vascular, Inc.'s 2032 outlook centres on $194.91, within a $148.51 to $274.24 range. That is up +9% on the projected 2031 average. That marks a +104% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, LMAT could reach as high as $287.75, with a base case around $201.92 and support toward $152.26 — roughly +111% from $95.72. Momentum favours further upside here.
Expect LMAT to range from $164.28 to $317.27 through 2034. The $220.03 average target implies a +130% move from current prices. That is up +9% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The LMAT price prediction for 2035 points to an average of $227.47 (low $168.25, high $331.62) — a potential gain of +138% on today's $95.72. Momentum favours further upside here.
In 2040, LMAT is projected to trade between $247.76 and $533.56, averaging $349.32 — a potential gain of +265% from today's $95.72. That is up +54% on the projected 2035 average. Buyers look set to stay in control over this stretch.
LeMaitre Vascular, Inc.'s 2050 outlook centres on $678.19, within a $448.52 to $1,110.14 range. That is up +94% on the projected 2040 average. That marks a +609% change versus current levels. Momentum favours further upside here.
Investing $1,000 in LMAT today (≈ 10.447137 LMAT) could be worth
$7,085.1
+$6,085.1 (+609%) by 2050 · US Dollar
Based on the average projected LMAT price of $678.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LMATwould be worth at today's price.
$1,000 invested in LMAT on May 27, 2025 (≈ 12.094823 LMAT) would be worth
$1,157.72
+$157.72 (+15.8%) today · 1.16× · US Dollar
Based on a LMAT entry price of $82.68 vs. today's $95.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $101.43 | $943.71 | -5.6% |
| 1 month ago | $114.52 | $835.84 | -16.4% |
| 3 months ago | $113.69 | $841.94 | -15.8% |
| 6 months ago | $82.95 | $1,153.95 | +15.4% |
| 1 year ago | $82.68 | $1,157.72 | +15.8% |
| All time (5.0y) ago | $51.5 | $1,858.64 | +85.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LMAT forecast.
Our base-case forecast reaches $190.00 around 2032.
Implied market cap at $190.00: $4.34B
The multi-year forecast suggests a sustained upside across years. In 2026 the avg price is $97.75 with a neutral sentiment and 0% ROI; in 2027 the avg price is $111.75 (ROI 14.3%, neutral); 2028 avg $119.98 (ROI 22.7%, bullish); 2029 avg $139.56 (ROI 42.8%, bullish); 2030 avg $158.91 (ROI 62.6%, bullish). Beyond, 2031–2035 show continued gains, with 2035 avg $248.63 (ROI 154.3%, bullish).
The long-range view extends to 2040 with avg $388.50 (ROI 297.4%, bullish) and 2050 with avg $766.84 (ROI 684.5%, bullish). These are estimates and not guarantees, and actual results may vary.
Tap a question to reveal the answer.
2030 avg $158.91; min $123.91; max $217.10; ROI 62.6%; sentiment bullish.
Forecasts show a path of rising averages from $97.75 in 2026 to $158.91 by 2030 and $766.84 by 2050, with ROIs of 0% in 2026, rising to 62.6% (2030) and 684.5% (2050); sentiment shifts to bullish from 2028 onward, though outcomes are not guaranteed.
Yes. The forecast for 2033 lists a max of $310.16, with an avg of $217.67 and a min of $164.14 (ROI 122.7%, bullish).
Avg $388.50; max $593.27; ROI 297.4%; sentiment bullish.
LeMaitre Vascular, Inc. Community Discussion
0Share your LeMaitre Vascular, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.